The UK and US have agreed to a landmark trade agreement that will maintain zero duties on British pharmaceutical shipments going into the American market.
Agreement Details of the Pact
As part of the deal, the UK has committed to increase funding on pharmaceuticals through the public health system. This pledge secures that tariffs on these vital goods will stay at nothing for a period of three years.
This deal comes after recent threats to hike import taxes on branded pharmaceutical imports, with increases mentioned reaching one hundred percent.
"This agreement between the Britain strengthens the global environment for new treatments and brings much-needed balance to transatlantic medicine commerce," an announcement noted.
Commercial Significance
Drugs are one of the UK's most significant export categories to the America, which is clearly the primary buyer for major companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months leading up to last September, the UK sold drugs valued at over eleven billion pounds to the US. This figure represented a significant portion of British export trade in that timeframe.
"This guarantee safeguards work, stimulates investment and facilitates the UK to emerge as a international leader for life sciences," the Business and Trade Secretary remarked.
Specific British Pledges
The pact includes several notable changes from the UK:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to raise total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The sum manufacturers must refund to the NHS to stay within budget will be limited at 15%. In the past, refunds exceeded twenty percent.
Broader Context
The deal follows a protracted dispute between the drug companies and the British authorities over drug pricing and NHS adoption.
This friction were exacerbated by assertions that American consumers were paying a premium for the same drugs than people in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS had to spend more on treatments, noting that its budget allocation on drugs had declined as a percentage of its total funding over the past decade.
